Euretos’ Post

Today, on World Alzheimer’s Day, we reflect on the challenges faced by millions of patients and families affected by this devastating disease.    At 3D-PharmXchange, we are honored to support Treeway in its mission to develop groundbreaking therapies for neurodegenerative diseases. One of the key projects we're involved in is the development of oral edaravone (TW001), which is currently being tested in the ASURE study, a Phase 2a clinical trial for mild-to-moderate Alzheimer's disease. This promising therapy has the potential to slow down disease progression by targeting oxidative stress, a critical component in the pathology of Alzheimer's.   Recently, Treeway announced that they have successfully completed enrolment for the ASURE study, marking a significant milestone in the development of TW001. This trial will evaluate the safety, tolerability, and potential efficacy of oral edaravone in patients with Alzheimer’s, and we are excited to be part of this pivotal journey.    Credits go to Bernard Muller, co-founder of Treeway (https://lnkd.in/e63bERj7) for sharing his artwork titled "Restoring the Colors of the Mind: The Stairway to a Healthy Brain"  This artwork was created with the assistance of text-to-image generative AI.    #WorldAlzheimersDay #DrugDevelopment #AlzheimersDisease #3DPharmXchange #Treeway #ClinicalResearch #Innovation #Collaboration #Neurodegeneration #biotech

As we mark #ParkinsonsAwarenessMonth, we are proud to share significant progress in our a-synuclein PET tracer program, bringing us closer to an imaging agent for the diagnosis of Parkinson’s Disease. ACI-12589 has proven specific and selective for a-syn, enabling us to visualize a-syn pathology in humans for the first time—a game changer for diagnosing multiple system atrophy and a leap towards #PrecisionMedicine. As we continue this journey, we are further leveraging our Morphomer platform to develop an imaging agent specifically optimized for #ParkinsonsDisease. Promising candidates such as ACI-15916 effectively bind to both large and smaller a-synuclein aggregates – crucial for detecting toxic proteins associated with Parkinson’s. The next-generation #asyn-PET tracer for PD is a critical step towards understanding and treating these complex diseases, much like how Abeta-PET has propelled Alzheimer’s clinical development. We are paving new paths in PD & MSA research, bringing hope to those affected by Parkinson's and MSA. For more details on our efforts to deliver the first PD tracer, watch Francesca Capotosti’s full presentation here: https://lnkd.in/gr6T5qK8 #ParkinsonsAwareness #NeurodegenerativeDiseases 

#WeeklyPodcast Ana Luzarraga-Aznar discussed about the molecular profile as predictor of #EndometrialRecurrence 🎙️ https://bit.ly/3Wu88g7 🔆Highlights 🧬Molecular subgroups of #endometrialcancer present distinctive recurrence patterns: p53-abn tumors relapse mostly with peritoneal and distant disease, and NSMP tumors at distance 🧬Molecular profile is a stronger independent predictor for vaginal, peritoneal, and distant recurrence than classic histologic factors 🧬P53-abn is the sole independent predictor of peritoneal relapse 🧬P53-abn and NSMP are independent predictors of #distantrecurrence #LeadArticle #IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc

🧠 Apollo Health Co , Neurocode Labs, Inc.’s BrainScan test can detect early-stage dementia BrainScan is designed to analyse three biomarkers to evaluate the risk of Alzheimer’s disease (AD) and other neurodegenerative conditions. It has adequate sensitivity to replace invasive and expensive spinal taps or PET brain scans. The three biomarkers include p-Tau 217, neurofilament light (NfL), and glial fibrillary acidic protein (GFAP). Read more online: https://lnkd.in/e2Rg2CzC 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

🧠 Big congratulations to Sage Cerebro Diagnostics for securing $307,538 from the The National Institutes of Health! Their project focuses on developing and validating a quantitative diagnostic biomarker for silent brain injury, particularly in the context of Alzheimer's disease and vascular dementia. This could be a game-changer in diagnosing and treating these conditions. #SBIR #STTR #Healthcare 🔍 This project grant will fund their research for 12 months, starting from September 4, 2024, to August 31, 2025. The goal is to create a minimally invasive diagnostic assay that can reliably detect cerebrovascular injury, improving the detection and stratification of cognitive impairment due to vascular damage. #Innovation #MedicalResearch

The negative results from Alector's INVOKE-2 trial in Alzheimer’s are yet another reminder that the traditional approach to neurodegenerative disease trials isn’t working: 🧠 Identify a promising mechanism (e.g., TREM-2 activation). ❌ Skip enriched populations tied to the mechanism to target a broader patient pool. 😐 Use subjective, low-sensitivity endpoints that demand large trials to detect any effect. ⏳ Mismatch biological timelines and trial durations due to budget constraints. 💔 Fail to show efficacy, leaving patients, researchers, investors, and clinicians disappointed. We’ve seen successes in SMA and DMD with functional endpoints, biomarker-enriched populations, and adaptive trial designs. It’s time to bring those lessons to Alzheimer’s and Parkinson’s trials. The current model isn’t just ineffective—it holds us all back. Let’s do better in 2025 and beyond.

C2N applauds the terrific work of CEOi - Global CEO Initiative on Alzheimer's Disease BBM Workgroup and the many experts who contributed their time, resources, and knowledge to develop an impactful guide that will significantly elevate the quality of blood biomarker tests for the benefit of patients dealing with cognitive concerns. We believe the guide highlights the importance of robust, rigorously-studied biomarkers. Indeed, we think these standards will pave the way for faster adoption of high-performing blood tests that will meet the criteria. The expert recommendations are available at Nature Portfolio Reviews Neurology. We appreciate the special recognition from the expert panel for the higher accuracy of Liquid Chromatography with tandem mass spectrometry (LC-MS-MS), and for the high bar the experts set for confirmatory testing. This is the high bar we also set for ourselves when we launched our PrecivityAD2 test in the U.S. last summer and more recently in Brazil and Australia via lab partners, Grupo Fleury and Healius Limited, respectively. All patients deserve the highest quality care. https://lnkd.in/eHTqqvNq. https://lnkd.in/edUWv9ri https://lnkd.in/eqefnnAu   #Alzheimers #Nature # #liquidbiopsy #CEOi #bloodbiomarkers #research #precisionmedicine

Day 3 of the 2024 World Medical Innovation Forum concluded with powerful insights into the urgent call for innovation in healthcare. A notable highlight was the panel discussion focused on unmet clinical needs, where panelists examined insights gathered from over 100 Mass General Brigham Harvard Medical School faculty regarding critical areas for advancement, including aging, brain health, and innovative cancer treatment strategies. These conversations emphasized the importance of collaboration and a comprehensive understanding of patient needs to drive impactful change within the healthcare landscape. For more, read the Day 3 recap: https://lnkd.in/dfha3AGz Missed a session? Visit our agenda page for session recordings: https://lnkd.in/exfpEwvS #WMIF2024 #Innovation #HealthcareInnovation #BostonBiotech #InnovationAtScale

Diagnosing Alzheimer's As of December 2024, the fight against Alzheimer’s has made significant strides on the diagnostic front. Among these advancements, p-tau (phosphorylated tau) blood tests stand out as revolutionary tools for early detection of the disease. Three p-tau tests have gained FDA Breakthrough Device Designation, expediting their development: >Quanterix Simoa® p-Tau 217: Uses ultra-sensitive technology to detect low-abundance tau proteins in blood. >Roche’s p-Tau 217 Blood Test: Focuses on tau pathology to aid in early diagnosis. >Fujirebio Lumipulse®: Combines p-tau 217 with β-amyloid ratios for a comprehensive diagnostic view. These tests work by measuring tau proteins associated with Alzheimer’s pathology in the blood, offering a less invasive and more accessible alternative to spinal taps or expensive brain imaging. These inventions are of significance because early detection and diagnosis means earlier interventions, better clinical outcomes, and improved quality of life for millions. #AlzheimersAwareness #EarlyDetection #InnovationInHealthcare

🌟 Exciting new research alert! 🌟 Maia Hare, a fourth-year medical student at the Zucker School of Medicine, and other researchers, have published a groundbreaking study on treatment differences in postmenopausal women with EIN, exploring race/ethnicity as a contributing factor. Endometrial cancer disparities are widening, especially affecting Black women with later-stage diagnoses and higher mortality rates. This study explores cultural barriers, socioeconomic status, access to care, comorbidities, and tumor histology, shining a light on critical, previously underexplored areas. Read the full study here 🔗 https://ow.ly/HRGA50S1XCL #MedicalResearch #HealthEquity #EndometrialCancer #WomenInMedicine #HealthcareDisparities #ZuckerSOM